Top 10 Companies Leading the Non-Replicating mRNA Vaccine Market Growth According to a newly published market research report by 24LifeSciences, global non-replicating mRNA vaccine market was valued at USD 1.34 billion in 2024 and is projected to reach USD 2.32 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.9% during the forecast period 2025-2032. Non-replicating mRNA vaccines represent a novel class of therapeutics based on messenger RNA technology, characterized by mRNA that does not replicate within the recipient's body. These vaccines work by delivering mRNA encoding specific antigens to human cells, prompting them to produce protein fragments that subsequently stimulate the immune system to generate both antibody production and T-cell activation. Due to their non-replicating nature, these vaccines are considered highly safe as they cannot cause infection or disease. The technology demonstrated significant advantages during the COVID-19 pandemic, establishing itself as a platform capable of rapid response to emerging health threats. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5190/non-replicating-mrna-vaccine-market